Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: Synthesis, characterization, X-ray structures and biological activity

Zn(II)-Chlorido Complexes of Phytohormone Kinetin and Its Derivatives Modulate Expression of Inflammatory Mediators in THP-1 Cells

“…Only 4 showed a slight toxic effect with an IC 50  = 10.9±1.1 µM. We cannot explain this phenomenon yet, however, it is possible, that 4 acts as a cyclin-dependent kinase inhibitor, in a similar way as the structurally resembling Zn(II) complexes with the derivatives of N6-benzyladenine [37]. Nevertheless, the interaction between 4 and its target protein has to be very specific, because structurally very similar complexes 1 – 3 and 5 did not demonstrate this effect.…”

Dinuclear copper(II) complexes containing 6-(benzylamino)purines as bridging ligands: Synthesis, characterization, and in vitro and in vivo antioxidant activities

“…This concentration of HCl was used for the first time for the preparation of copper(II) complexes with the Bap derivatives. Surprisingly, no protonation of the Bap ligands occurred during the syntheses of the complexes in contrast to zinc(II) complexes involving 6-(benzylamino)purine-based CDK inhibitors as ligands, where the ligands were single protonated [16]. The copper(II) complexes 5-7 were synthesized in ethanol.…”

Zinc(II) chlorido complexes of protonated kinetin and its derivatives: Synthesis, properties and X-ray structure of [Zn(Hkinetin)Cl3]·kinetin

“…Recently, we have reported the preparation and characterization of Zn(II) complexes involving the cytokinin-derived cyclin dependent kinase inhibitors Olomoucine [2-(2-hydroxyethylamino)-6-benzylamino-9-methylpurine], i-propyl-Olomoucine [2-(2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine] and Bohemine 0020-1693/$ -see front matter Ó 2010 Elsevier B.V. All rights reserved. doi:10.1016/j.ica.2010.08.040 [2-(3-hydroxypropylamino)-6-benzylamino-9-isopropylpurine] [9]. The in vitro cytotoxicity of the Zn(II) complexes against human melanoma (G-361), osteosarcoma (HOS), myelogenous leukaemia (K-562) and breast adenocarcinoma (MCF-7) cell lines has been determined as well as the inhibition of the CDK2/cyclin E kinase.…”